这款在研疗法已经被美国FDA授予快速通道资格,用于治疗携带特定基因突变的非小细胞肺癌经治患者。它目前在临床试验中作为单药或与抗PD-L1抗体Tecentriq联用,治疗晚期实体瘤患者。Dracen去年已经与默沙东达成合作,将在临床试验中评估DRP-104与抗PD-1抗体Keytruda联用的效果。 在脂质代谢方面,肿瘤细胞依赖脂肪酸的从头合成(de novo synthesis)进行增长和繁殖,因此它们可能对抑制脂肪酸合成酶活性的抑制剂敏感。在脂肪酸的合成过程中,多款合成酶可以成为潜在的药物靶点。
[1] Stine et al., (2021). Targeting cancer metabolism in the era of precision oncology. Nature Reviews Drug Discovery, https://doi.org/10.1038/s41573-021-00339-6
[2] DRACEN PHARMACEUTICAL’S DRP-104 GRANTED U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER. Retrieved January 26, 2022, from https://www.dracenpharma.com/dracen-pharmaceuticals-drp-104-granted-u-s-fda-fast-track-designation-for-the-treatment-of-non-small-cell-lung-cancer/
[3] FASN抑制剂研发迎突破,癌症代谢能否成为抗癌药物开发的下一个主流?| 歌礼CEO吴劲梓博士独家点评. Retrieved January 26, 2022, from https://mp.weixin.qq.com/s?__biz=MzUxMTY5MzM5OQ==mid=2247509622idx=1sn=cc5388b8e3f8bc14da18d5d8ddb78a62
[4] About Cancer Cell Metabolism. Retrieved January 26, 2022, from https://rafaelpharma.com/wp-content/uploads/Rafael-Website-Cancer-Metabolism-Backgrounder-1.pdf
[5] CPI-613® (devimistat): A First-in-Class Therapeutic Agent Targeting Cancer Cell Metabolism. Retrieved January 26, 2022, from https://rafaelpharma.com/wp-content/uploads/Rafael-Pharma_CPI-613%C2%AE-devimistat_Fact-Sheet.pdf
[6] Sidney Farber, MD, A career in cancer research driven by the power of an idea. Retrieved January 26, 2022, from https://www.dana-farber.org/about-us/history-and-milestones/sidney-farber,-md/
[7] FASN. Retrieved January 28, 2022, from https://sagimet.com/fasn/